The CAGR for the cold, cough, and sore throat remedy market from 2024 to 2034 is expected to stand at 3.40%. Innovations of advanced remedies and drugs with varied dose forms to curate the needs of all age groups are a current necessity.
The market is set to be valued at US$ 42,618.7 million in 2024. The promising nature of the pharma sector in emerging economies sees an uptrend in market valuation, projected to turn figures to US$ 59,539.6 million by 2034.
| Attributes | Key Statistics |
|---|---|
| Expected Base Year Value (2024) | US$ 42,618.7 million |
| Anticipated Forecast Value (2034) | US$ 59,539.6 million |
| Estimated Growth (2024 to 2034) | 3.40% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to the World Health Organization (WHO), acute respiratory infections are one of the foremost causes of morbidity. This affects millions of people every year. With this, the demand for cold, cough, and sore throat medicines becomes prominent.
Increasing awareness of over-the-counter medicines is making these drugs popular choices among consumers. OTC medicines are easily accessible and do not require a prescription. This availability has led to a gain in self-medication trends, fueling market growth. Also, the market is highly competitive, with a wide range of options available.
Manufacturers are constantly innovating and introducing new products, meeting the set preferences. For instance, the market has seen the introduction of combination drugs that offer relief from multiple symptoms, such as cough, congestion, and sore throat, in a single dose. Such products boost the market.
Another factor supporting market growth is the rising geriatric population. Elderly individuals are more susceptible to respiratory infections and illnesses. This factor is making them a key target demographic for cold, cough, and sore throat remedies. With the consumer base aging, such remedies are expected to evolve in the foreseeable future.
The market’s obvious growth does not make it immune to certain drawbacks. Several factors devaluate the market growth.
These also connect to economic factors such as changes in healthcare spending and insurance coverage. All these factors influence consumer behavior and keep down market growth.
Principal Consultant
Antihistamines are anticipated to hold a significant share value of 27.00% in the cold, cough, and sore throat remedy market for 2024.
| Attributes | Details |
|---|---|
| Drug Type | Antihistamines |
| Market Share (2024) | 27.00% |
Antihistamines are the most commonly used drug because they treat allergic reactions and reduce symptoms such as runny nose, sneezing, and itchy eyes. They are also popular due to their widespread use and availability in both prescription and over-the-counter forms. This makes the antihistamines industry highly competitive, with a wide range of options available to consumers.
Antihistamines are available in different forms, like pills, liquids, and nasal sprays. This adds convenience to consumers looking for fast and effective relief from cold and cough symptoms. Manufacturers have scope to move forward with wide production of these drug types to enhance market growth.
In the highly competitive cold and cough industry, oral syrups are set to gain a significant market share of 33.20% in 2024.
Oral syrups treat a variety of symptoms. These include cough, sore throat, and nasal congestion, making them convenient for consumers looking for fast and effective relief. Oral syrups, as medication doses for managing colds, coughs, and sore throats, are frequently prescribed for pediatric patients and the elderly. Thus, the oral syrups segment is skyrocketing as they cover all age groups and are effective for varied symptoms.
| Attributes | Details |
|---|---|
| Doses Type | Oral Syrups |
| Market Share (2024) | 33.20% |
| Countries | CAGR from 2024 to 2034 |
|---|---|
| India | 7.40% |
| Poland | 5.30% |
| Brazil | 4.40% |
| China | 4.30% |
| United States | 2.00% |
India is gaining market prominence with an attributed blend of trusted formulations of Ayurveda, aggressive marketing strategies, and a wide distribution network. Innovation in new product variants, leveraging natural ingredients, and a whole focus on consumer education are making the Indian market touch the skies. With the notable trends of e-commerce and advanced formulations, India is marking a market share of 7.40% from 2024 to 2034.
Brands such as Dabur, Himalaya Wellness, Zandu, Patanjali Ayurved, and Hamdard are among the prominent ones in the country. These brands have long-established reputations for offering traditional herbal remedies and over-the-counter pharmaceutical products.
Partnerships and collaboration with healthcare professionals and institutions create brand credibility and promote trusted products. Setting a strong consumer base and key players capitalizing growing demand for cold and cough remedies, the Indian market is growing and is likely to have a continuum of it through the forecast period.
Significant presence of well-established pharmaceutical companies such as Polpharma, Aflofarm, and Herbapol Kraków offering a wide range of OTC and herbal remedies advances the market in Poland. With an expected CAGR of 5.30% through 2034, Polish players are likely to cater to the market demand of consumers looking for natural and culturally rooted solutions for cold and flu symptoms.
Polish brands are exploring opportunities for international expansion, seeking to tap into new markets beyond Poland's borders. Partnerships with pharmacies also play a crucial role in expansion aiming at increasing distribution channels. In all, Polish market players and manufacturers are committed to acquiring more of a share with innovation and strategic growth initiatives to maintain the competitive edge.
Brazil, with an anticipated CAGR of 4.40% through 2034, is seeing the introduction of products tailored to the needs of Brazilian consumers.
Brazil counts pharmaceutical giants like Johnson & Johnson, GlaxoSmithKline (GSK), and Bayer AG as having a presence in its borders. These key companies have long-established brands such as Tylenol, Benadryl, and Aspirin, which consumers widely recognize and trust.
These players are developing formulations addressing prevalent symptoms experienced during cold and flu seasons in Brazil. Thus, drugs for symptoms such as humidity-induced congestion and sore throats aggravated by air pollution have boosted the drug sector.
Emerging trends of natural and herbal remedies in the Brazilian market are prompting companies to explore plant-based ingredients and traditional remedies. Johnson & Johnson, GSK, and Bayer AG are actively incorporating such ingredients into their product lines to cater to the wide consumer base.
The China market, with an expected CAGR of 4.30% from 2024 to 2034, is likely to grow broadly in the healthcare sector by implementing advanced technologies.
Growth in China’s cold, cough, and sore throat remedy market is driven by the rising geriatric population, the rise in the number of people suffering from acute and chronic cough, favorable government support, and easy availability of OTC medications at low prices.
The Panel of Chinese Thoracic Society (CTS) Asthma Consortium published the first version of the Chinese Guidelines for Diagnosis and Treatment of Cough in 2005 (revised 2009) to standardize the diagnosis and treatment of acute and chronic cough, thereby offering advice for clinical practice. This has accelerated the growth of innovations in novel cold and cold remedies. With these advancements, the country holds a large share of production and sales of the cold and cough remedies industry.
The United States market is projected to develop at a CAGR of 2.00% through 2034.
Advances in clinical care settings and the availability of health schemes for children and adults for the management of colds, coughs, and sore throats are the prime factors in the United States driving the growth of the market. High levels of health awareness among people and the presence of some of the leading pharmaceutical giants are contributing to the United States cold, cough, and sore throat remedy market.
As per the Asthma and Allergy Foundation of America (AAFA), over 50 million Americans experience various types of allergies each year. In the USA over 70% of cough cold medicines are non-prescription medicines. This is marking a steady growth for the cold and sore throat remedy sector in the coming years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Market players are adopting various strategies to expand their market share. Some players are focusing on developing innovative products with improved efficacy and safety profiles. Laterally, others are investing in marketing and promotional activities to increase brand awareness and reach a wider customer base.
Mergers with healthcare providers and retailers are being formed to improve distribution and increase accessibility of these products. The market is also witnessing an increasing trend of online sales and e-commerce platforms.
Recent Advancements
The market is set to reach US$ 42,618.7 million in 2024.
The market is expected to reach US$ 59,539.6 million by 2034.
The market is in line to develop at a CAGR of 3.40 % from 2024 to 2034.
Oral syrups are pegged to be the top dose type, with a market share of 33.20% for 2024.
The market in India is expected to progress at a CAGR of 7.40% through 2034.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Manufacturer 3.5.1.2. Mid-Level Participants (Traders) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Drug, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Drug, 2024 to 2034 5.3.1. Antihistamines 5.3.2. Expectorants 5.3.3. Bronchodilators 5.3.4. Decongestants 5.3.5. Antibiotics 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Drug, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Drug, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Doses 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Doses, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Doses, 2024 to 2034 6.3.1. Oral Syrups 6.3.2. Tablets/Pills 6.3.3. Nasal Drops 6.3.4. Lozenges 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By Doses, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Doses, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Drug Stores 7.3.4. Supermarkets/Hypermarkets 7.3.5. E-Commerce/Online Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug 9.2.3. By Doses 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug 9.3.3. By Doses 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug 10.2.3. By Doses 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug 10.3.3. By Doses 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Drug 11.2.3. By Doses 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug 11.3.3. By Doses 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Drug 12.2.3. By Doses 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug 12.3.3. By Doses 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Drug 13.2.3. By Doses 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug 13.3.3. By Doses 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug 14.2.3. By Doses 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug 14.3.3. By Doses 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug 15.2.3. By Doses 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug 15.3.3. By Doses 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2023 16.1.2.1. By Drug 16.1.2.2. By Doses 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2023 16.2.2.1. By Drug 16.2.2.2. By Doses 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2023 16.3.2.1. By Drug 16.3.2.2. By Doses 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2023 16.4.2.1. By Drug 16.4.2.2. By Doses 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2023 16.5.2.1. By Drug 16.5.2.2. By Doses 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2023 16.6.2.1. By Drug 16.6.2.2. By Doses 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2023 16.7.2.1. By Drug 16.7.2.2. By Doses 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2023 16.8.2.1. By Drug 16.8.2.2. By Doses 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2023 16.9.2.1. By Drug 16.9.2.2. By Doses 16.9.2.3. By Distribution Channel 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2023 16.10.2.1. By Drug 16.10.2.2. By Doses 16.10.2.3. By Distribution Channel 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2023 16.11.2.1. By Drug 16.11.2.2. By Doses 16.11.2.3. By Distribution Channel 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2023 16.12.2.1. By Drug 16.12.2.2. By Doses 16.12.2.3. By Distribution Channel 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2023 16.13.2.1. By Drug 16.13.2.2. By Doses 16.13.2.3. By Distribution Channel 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2023 16.14.2.1. By Drug 16.14.2.2. By Doses 16.14.2.3. By Distribution Channel 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2023 16.15.2.1. By Drug 16.15.2.2. By Doses 16.15.2.3. By Distribution Channel 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2023 16.16.2.1. By Drug 16.16.2.2. By Doses 16.16.2.3. By Distribution Channel 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2023 16.17.2.1. By Drug 16.17.2.2. By Doses 16.17.2.3. By Distribution Channel 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2023 16.18.2.1. By Drug 16.18.2.2. By Doses 16.18.2.3. By Distribution Channel 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2023 16.19.2.1. By Drug 16.19.2.2. By Doses 16.19.2.3. By Distribution Channel 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2023 16.20.2.1. By Drug 16.20.2.2. By Doses 16.20.2.3. By Distribution Channel 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2023 16.21.2.1. By Drug 16.21.2.2. By Doses 16.21.2.3. By Distribution Channel 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2023 16.22.2.1. By Drug 16.22.2.2. By Doses 16.22.2.3. By Distribution Channel 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2023 16.23.2.1. By Drug 16.23.2.2. By Doses 16.23.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug 17.3.3. By Doses 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Reckitt Benckiser Group PLC 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.1.5.2. Product Strategy 18.1.1.5.3. Channel Strategy 18.1.2. Johnson & Johnson Services, Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.2.5.2. Product Strategy 18.1.2.5.3. Channel Strategy 18.1.3. GlaxoSmithKline plc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.3.5.2. Product Strategy 18.1.3.5.3. Channel Strategy 18.1.4. Novartis AG 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.4.5.2. Product Strategy 18.1.4.5.3. Channel Strategy 18.1.5. Bayer AG 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.5.5.2. Product Strategy 18.1.5.5.3. Channel Strategy 18.1.6. AstraZeneca plc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.6.5.2. Product Strategy 18.1.6.5.3. Channel Strategy 18.1.7. Sun Pharmaceutical Industries Ltd. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.7.5.2. Product Strategy 18.1.7.5.3. Channel Strategy 18.1.8. Pfizer Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.8.5.2. Product Strategy 18.1.8.5.3. Channel Strategy 18.1.9. Prestige Brands Holdings, Inc. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.9.5.2. Product Strategy 18.1.9.5.3. Channel Strategy 18.1.10. Procter & Gamble Co. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.10.5.2. Product Strategy 18.1.10.5.3. Channel Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Cold, Cough, and Sore Throat Remedy Market
